Good morning. This is Jonathan with you once more. We’re now close enough to the weekend that it’s time to start making plans (or looking forward to the ones you’ve made), but far enough that there’s still plenty of work to do. Oh, the agony. Hope these engaging news items help ease the pain.
The Food and Drug Administration authorized new Covid booster shots that more closely match the strains of the coronavirus currently circulating in the U.S., STAT tells us. The FDA decision, which came yesterday, still requires the signoff of the Centers for Disease Control and Prevention. The agency’s vaccine advisory panel is scheduled to meet today and tomorrow, and could vote to recommend them as early as today.
Sanofi has secured FDA approval for the enzyme replacement therapy Xenpozyme, a treatment for a deadly rare disease, according to Endpoints. The drug replaces a missing enzyme that the body needs to break down a lipid that otherwise builds up in the spleen, lung, and liver, leading to intense pain and difficulty breathing and eating. There are fewer than 120 patients diagnosed in the U.S. with the condition it targets, known as Niemann-Pick disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect